Erectile Dysfunction (Condition)
At a glance
- Assess: clarify erection, libido, ejaculation and relationship goals; use a validated symptom measure, focused examination, medication review and metabolic/morning-testosterone assessment. Review cardiovascular risk and suitability for sexual activity.[22]
- Options: address reversible factors and offer psychosexual support alongside PDE5 inhibitors, vacuum device, intraurethral or intracavernosal therapy, or prosthesis according to informed preference. Review technique and tolerability before labelling a medication ineffective.[22]
- Reconsider the pathway: nitrate use contraindicates PDE5 inhibitors; assess unstable/high-risk cardiovascular disease before sexual activity. Testosterone requires a confirmed deficiency assessment. Implant surgery requires absence of active infection.[22][12]
- Follow-up: reassess goal attainment, correct use, adverse effects and partner concerns. After nerve-sparing prostatectomy, distinguish assisted erections during treatment from unassisted recovery; REACTT did not show improved recovery after washout.[22][24]
Compare pivotal on-treatment efficacy and postoperative recovery evidence. Prescribing details remain in the pharmacology hubs.
Erectile dysfunction (ED) is the consistent or recurrent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance.[1][2] It is one of the most common male sexual dysfunctions, affecting approximately 40% of men aged 40–49 and rising to 50–100% of men over 70.[1] An older modelling projection estimated 322 million cases by 2025; this is not a measured contemporary global count.[1][3]
For the operative treatment atlas (penile prosthesis, revascularization, Peyronie's surgery as comorbid disease) see Sexual Dysfunction Treatment Atlas. For the pharmacology hubs (PDE5 inhibitors, intracavernosal injection agents, intraurethral alprostadil, testosterone replacement, androgen adjuncts, priapism management) see Sexual Medicine & Andrology.
Pathophysiology
Erection is a neurovascular event requiring coordination of psychological, endocrine, vascular, and neurological systems. Parasympathetic stimulation triggers release of nitric oxide (NO) from endothelial cells and nonadrenergic noncholinergic neurons, which activates guanylyl cyclase to produce cyclic GMP (cGMP). cGMP causes smooth-muscle relaxation in the corpora cavernosa, increasing arterial inflow and compressing subtunical venules to trap blood and produce rigidity. PDE5 inhibitors prolong this signal by blocking cGMP degradation.[1][4]
ED is classified as psychogenic, organic, or — most commonly — mixed:[1][2]
| Class | Mechanism | Examples |
|---|---|---|
| Vasculogenic | Arterial insufficiency, corporal veno-occlusive dysfunction (venous leak), sinusoidal fibrosis | Atherosclerosis, post-radiation, post-traumatic |
| Neurogenic | Central or peripheral neural disruption | Stroke, MS, spinal-cord injury, diabetic neuropathy, post–radical pelvic surgery |
| Endocrinological | Testosterone, prolactin, thyroid axis | Hypogonadism, hyperprolactinemia, diabetes mellitus |
| Drug-induced | Pharmacologic interference with NO / sympathetic balance | Antihypertensives, SSRIs, antiandrogens, major tranquilizers |
| Psychogenic | Performance anxiety, depression, relationship dynamics | ~ 20% of presentations[3][5] |
Risk Factors
Age is the dominant risk factor; type 2 diabetes mellitus is the second, with ED in 50–75% of diabetic men.[1] Other key contributors:[1][5][4]
- Hypertension — ED prevalence up to 68%
- Dyslipidemia
- Obesity and metabolic syndrome
- Sedentary lifestyle
- Cigarette smoking — doubles ED prevalence vs nonsmokers
- Alcohol and recreational drug use
- Lower urinary tract symptoms / BPH
- Depression
- Prostate-cancer treatment — radical prostatectomy, radiation, brachytherapy
ED as a Cardiovascular Risk Marker
ED and cardiovascular disease (CVD) share the same pathophysiology — endothelial dysfunction and atherosclerosis.[1][6] Because penile arteries are smaller-caliber than coronary arteries, the same degree of endothelial dysfunction manifests earlier in erectile tissues.
The Mostafaei 2021 umbrella review of meta-analyses confirmed that ED independently predicts:[7]
| Outcome | Relative risk |
|---|---|
| Cardiovascular disease | 1.45 |
| Coronary heart disease | 1.50 |
| Myocardial infarction | 1.55 |
| Stroke | 1.36 |
| All-cause mortality | 1.25 |
ED can precede symptomatic coronary disease, but the interval and proportion depend on the population studied; the Dong meta-analysis evaluated future cardiovascular risk, not a universal two-thirds presentation rule.[8][4] The current EAU framework incorporates Princeton IV cardiovascular assessment. ED is a risk marker; urgency and referral depend on cardiovascular symptoms and the individual risk assessment.[22]
Diagnostic Evaluation
Evaluation begins with a thorough sexual, medical, and psychosocial history and a focused physical examination of the genitourinary, endocrine, vascular, and neurological systems.[9][10]
Validated questionnaire — IIEF-5 (Sexual Health Inventory for Men)
| Score | Severity |
|---|---|
| 5–7 | Severe ED |
| 8–11 | Moderate ED |
| 12–16 | Mild-to-moderate ED |
| 17–21 | Mild ED |
| 22–25 | None |
The IIEF-5 is the standard screening and outcomes-tracking instrument across ED trials and contemporary practice.[2]
Laboratory testing
- Fasting glucose / HbA1c — diabetes screen
- Lipid panel — atherosclerotic risk
- Morning total testosterone — repeat if abnormal; if low, add free testosterone and LH to differentiate primary vs secondary hypogonadism
- Selected: prolactin, TSH when clinically indicated[9][10]
Specialized tests (selected cases)
- Nocturnal penile tumescence (NPT) — psychogenic vs organic differentiation
- Intracavernosal injection (ICI) test — assesses vasculogenic component
- Penile duplex Doppler ultrasound — peak systolic velocity (arteriogenic), end-diastolic velocity (veno-occlusive)
- Cavernosometry / cavernosography — when surgical revascularization is being considered
- Selective pudendal arteriography — pre-revascularization in young men with focal post-traumatic disease[9]
Cardiovascular risk assessment
Assess cardiovascular risk and the safety of sexual activity. The EAU 2026 framework incorporates Princeton IV, including risk assessment for predominantly vasculogenic ED and further evaluation when risk is uncertain or high.[22]
Treatment
Treatment uses shared decisions across the available options. The EAU 2026 framework replaces a rigid three-tier ladder with choices based on efficacy, invasiveness, safety and patient preference; the AUA 2018 and ICSM guidance provide additional context.[22][12][13]
1. Lifestyle modification — the foundation
The AUA guideline recommends counseling on tobacco cessation, regular exercise, weight loss, and improved control of diabetes, hypertension, and dyslipidemia. These interventions improve erectile function and overall cardiovascular health.[12][5]
2. First-line — oral PDE5 inhibitors
PDE5 inhibitors are an established first-line pharmacotherapy; response depends on cause, correct use and the outcome definition.[1][12][13] See the PDE5 inhibitors pharmacology hub for the deep dive on mechanisms, dosing, contraindications, and post-RP rehab evidence.
Use the prescribing hub for agent selection, starting doses, adjustment and contraindications. Avoid interpreting an intercourse-attempt success rate as a patient-level cure rate.
Key prescribing principles:
- Try at least 4–6 times before deeming ineffective.[1][15]
- Review stimulation, timing, food effects, adherence and safe dose adjustment; patients may select another modality without exhausting every oral regimen.[12][22]
- Absolute contraindication: concurrent nitrate use — risk of severe hypotension.[14]
- Caution with α-blockers (orthostatic hypotension) and patients with autonomic dysfunction.[15][14]
- Common side effects: headache, flushing, dyspepsia, nasal congestion, visual disturbances.
- No clinically significant efficacy difference among the four agents; choice is driven by patient preference (onset, duration, daily-vs-on-demand).[13]
3. Injection, intraurethral and device options
For inadequate oral response, contraindications, or informed preference:[12][16][17]
- Intracavernosal injection (ICI) — alprostadil monotherapy or bimix / trimix / quadmix combinations. ICI is the most reliably effective non-surgical option in PDE5-resistant patients. Risks: priapism (~ 1.8% with alprostadil), injection-site pain, and penile fibrosis (4.5–13%). See the ICI agents pharmacology hub.
- Intraurethral alprostadil (MUSE) — less invasive than ICI but typically less effective; useful when ICI is not tolerated. See intraurethral alprostadil.
- Vacuum erection device (VED) — non-invasive, mechanical option particularly suitable for patients who cannot use pharmacotherapy or for post-RP penile-rehabilitation programs.
4. Penile prosthesis
Surgically implanted inflatable or malleable penile prostheses may be selected after discussion of all options, including when other treatment is ineffective or unacceptable. Multicomponent inflatable prostheses (IPPs) achieve > 90% patient and partner satisfaction in contemporary series — among the highest satisfaction rates of any urologic prosthetic surgery.[12][10] Surgery should not be performed in the presence of active infection.[12]
For the operative pathway — preoperative evaluation (CURSED), intraoperative setup (no-touch), approaches (PS / IP / SC), reservoir placement (SoR / HSM), models database, infection prevention, revision, and complications — see Penile Implants.
5. Testosterone replacement therapy
In men with confirmed hypogonadism (total testosterone < 300 ng/dL on two morning measurements with concordant symptoms), testosterone replacement improves IIEF erectile-function scores.[19][20] Benefit is greater in men with more severe hypogonadism (T < 250 ng/dL).[20] TRT may be combined with PDE5 inhibitors for enhanced effect in hypogonadal men with ED.[20][16]
The Endocrine Society 2018 guideline recommends baseline prostate-cancer risk assessment before initiation and monitoring for thromboembolism on therapy.[19] The TRAVERSE 2023 trial and the Bhasin & Snyder 2025 NEJM review clarified the contemporary cardiovascular safety profile (non-inferiority for MACE).[21] See the testosterone replacement pharmacology hub for the full framework.
6. Emerging therapies
- Low-intensity extracorporeal shockwave therapy (Li-ESWT) — proposed mechanism: neovascularization and tissue regeneration. The 2025 Cochrane review (21 trials, 1,357 men) found low-certainty evidence: the average short-term erectile-function benefit may be too small to be clinically important; longer-term benefit remains uncertain and heterogeneous. EAU offers a weak recommendation for selected vasculogenic ED, whereas AUA considers treatment investigational. This is not established restorative therapy.[2][18]
- Stem-cell and platelet-rich-plasma (PRP) therapy — investigational; EAU limits intracavernosal PRP to clinical trials. Small positive studies do not establish routine efficacy.[18]
7. Psychosexual therapy
Counseling is recommended for men with psychogenic ED, either as monotherapy or in combination with pharmacotherapy. Couples-based therapy is particularly valuable when relationship dynamics contribute. Cochrane 2007 showed group therapy + sildenafil > sildenafil alone (RR 0.46 for persistence of ED) and a small RCT showed group therapy alone superior to sildenafil on IIEF.[5][14] See the canonical Psychosexual Therapy page for the full sensate focus / CBT / MBI / PLISSIT framework.
Special Populations
| Population | Key considerations |
|---|---|
| Post-radical prostatectomy | Offer erectile-function treatment; REACTT improved assisted function during treatment but did not establish unassisted recovery after washout. Discuss PDE5i, MUSE, ICI, VED and prosthesis according to goals.[24] |
| Post-pelvic radiation | Vasculogenic + neurogenic mechanism; PDE5i first-line; ICI / IPP for non-response |
| Diabetes mellitus | High prevalence (50–75%); poorer PDE5i response; lower threshold for second-line[17] |
| Spinal-cord injury / MS | Neurogenic mechanism; PDE5i first-line; autonomic-dysreflexia precaution in lesions T6 and above (see Autonomic Dysreflexia)[15] |
| Cardiovascular disease | Princeton IV-informed risk stratification; nitrate use is an absolute contraindication to PDE5i[11] |
| Young men with focal post-traumatic disease | Selective candidates for penile revascularization — see saphenous vein graft |
| Peyronie's disease overlap | Treat ED with PDE5i first; surgical correction of curvature combined with IPP if both present — see Peyronie's disease |
Prognosis and Key Takeaways
ED is a treatable condition at all stages. The diagnosis should prompt cardiovascular risk assessment, as it may precede symptomatic CVD by several years (the interval varies by population).[7][1][6][8]
Discuss lifestyle and psychosexual care alongside medication, injection/device therapy and prosthesis. Avoid promising the same success rate across different causes or presenting surgery as a mandatory last step.[12][22]
For the reconstructive urologist, ED management runs in parallel with penile-implant and Peyronie's-disease practice. New ED warrants cardiovascular assessment; cardiology referral depends on symptoms, risk and uncertainty rather than being automatic for every patient.
Selected evidence
Sildenafil pivotal trials · 1998[23]; REACTT · 2014[24]. The comparison below preserves the study-specific population, denominator, endpoint and uncertainty.
Selected studies, not a systematic review. Outcomes and populations differ; percentages across studies should not be ranked as if they were directly comparable. These source checks do not record a clinician review of the full article.
| Study and population | Comparison and results | Use and limitations |
|---|---|---|
| Sildenafil pivotal trials · 1998 Men with erectile dysfunction of organic, psychogenic or mixed causes. Randomized n=861 | Sildenafil vs placebo Successful intercourse attempts · Final 4 weeks of the 12-week trial 69% of attempts with sildenafil vs 22% with placebo. P<.001; confidence interval not reported in inspected abstract. | Demonstrates on-treatment efficacy; not proof that spontaneous erectile function is restored.
Correction notice recorded. See source and methods. |
| REACTT · 2014 Men ≤68 with normal preoperative erectile function undergoing bilateral nerve-sparing radical prostatectomy. Randomized n=423 | Daily or on-demand tadalafil vs placebo Unassisted IIEF-EF ≥22 after drug washout · 9 months treatment followed by 6-week washout 20.9% daily, 16.9% on-demand, 19.1% placebo. Odds ratio vs placebo: daily 1.1 (95% CI 0.6–2.1); on-demand 0.9 (0.5–1.7). | PDE5 inhibitors may assist erections after surgery; do not promise improved spontaneous recovery from a rehabilitation schedule.
|
See Also
- Sexual Dysfunction Treatment Atlas
- Penile Implants
- Peyronie's Disease
- PDE5 Inhibitors
- Intracavernosal Injection Agents
- Intraurethral Alprostadil
- Testosterone Replacement
- Saphenous Vein Graft — penile revascularization
- Priapism Management — for ICI-related complications
References
1. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–65. doi:10.1016/S0140-6736(12)60520-0
2. Ergun O, Kim K, Kim MH, et al. Low-intensity shockwave therapy for erectile dysfunction. Cochrane Database Syst Rev. 2025;7:CD013166. doi:10.1002/14651858.CD013166.pub3
3. Lee HW, Lee MS, Kim TH, et al. Ginseng for erectile dysfunction. Cochrane Database Syst Rev. 2021;4:CD012654. doi:10.1002/14651858.CD012654.pub2
4. McVary KT. Erectile dysfunction. N Engl J Med. 2007;357(24):2472–81. doi:10.1056/NEJMcp067261
5. Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820–7.
6. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65(5):968–78. doi:10.1016/j.eururo.2013.08.023
7. Mostafaei H, Mori K, Hajebrahimi S, et al. Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. BJU Int. 2021;128(1):3–11. doi:10.1111/bju.15313
8. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85. doi:10.1016/j.jacc.2011.06.024
9. Lee H, Hwang EC, Oh CK, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024;1:CD013071. doi:10.1002/14651858.CD013071.pub2
10. McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019;210(10):469–76. doi:10.5694/mja2.50167
11. Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nat Rev Cardiol. 2022;19(1):59–74. doi:10.1038/s41569-021-00593-6
12. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–41. doi:10.1016/j.juro.2018.05.004
13. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–88. doi:10.1016/j.jsxm.2016.01.016
14. Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion. Fertil Steril. 2023;120(5):967–72. doi:10.1016/j.fertnstert.2023.07.001
15. Hentzen C, Musco S, Amarenco G, Del Popolo G, Panicker JN. Approach and management to patients with neurological disorders reporting sexual dysfunction. Lancet Neurol. 2022;21(6):551–62. doi:10.1016/S1474-4422(22)00036-9
16. Lee M, Sharifi R. Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails. Drugs Aging. 2018;35(3):175–87. doi:10.1007/s40266-018-0528-4
17. Hatzimouratidis K, Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14(11):545. doi:10.1007/s11892-014-0545-6
18. Wang CM, Wu BR, Xiang P, Xiao J, Hu XC. Management of male erectile dysfunction: from the past to the future. Front Endocrinol. 2023;14:1148834. doi:10.3389/fendo.2023.1148834
19. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44. doi:10.1210/jc.2018-00229
20. Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on International Index of Erectile Function scores. Eur Urol. 2017;72(6):1000–11. doi:10.1016/j.eururo.2017.03.032
21. Bhasin S, Snyder PJ. Testosterone treatment in middle-aged and older men with hypogonadism. N Engl J Med. 2025;393(6):581–91. doi:10.1056/NEJMra2404637
22. European Association of Urology. Sexual and Reproductive Health Guidelines, 2026 edition. Management of erectile dysfunction. Accessed September 11, 2026.
23. Goldstein I et al. Oral Sildenafil in the Treatment of Erectile Dysfunction. 1998. doi:10.1056/NEJM199805143382001.
24. Montorsi F et al. Effects of Tadalafil Treatment on Erectile Function Recovery Following Bilateral Nerve-sparing Radical Prostatectomy: A Randomised Placebo-controlled Study (REACTT). 2014. doi:10.1016/j.eururo.2013.09.051.